Results 61 to 70 of about 25,012 (219)

Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”

Frontiers in Psychiatry
BackgroundChronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best ...
Julia Bornemann, James B. Close, Kirran Ahmad, Tommaso Barba, Kate Godfrey, Lauren Macdonald, David Erritzoe, David Nutt, Robin Carhart-Harris, Robin Carhart-Harris   +9 more
doaj   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

Synthesizing Attachment Theory with the REBUS Model : An Agenda Proposal for Psychedelic Science

In this chapter, the authors synthesize the relational developmental perspective of attachment theory with a neuroscientific model: the RElaxed Beliefs Under pSychedelics (REBUS).
Mikulincer, Mario, Granqvist, Pehr,, Gruneau Brulin, Joel,, Östlind, Sebastian,, Cherniak, Aaron D.,, Carhart-Harris, Robin   +5 more
core   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial

Communications Medicine
Background Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn’t been studied in U.S. military Veterans, who face higher symptom severity and suicide risk.
Stacey B. Armstrong, Adam W. Levin, Nathan D. Sepeda, Hillary Shaub, Taweh Hunter, Angela Douglas, Rafaelle Lancelotta, Alan K. Davis   +7 more
doaj   +1 more source

Breathing in Plants and Chaos—Cosmic Tree Events in Cameroon and Beyond

Anthropology of Consciousness, EarlyView.
ABSTRACT Contemporary practices of tapping into the wisdom of ancestral trees are described through three entangled recent events lived within the context of Bantu practices in Cameroon. In the three instances, the steered or chance encounters with high potency trees were serendipitous telling moments which brought something new to the horizon.
Julie Laplante, Armel Lekeufack, Nina Tamara Barbosa Ponce, Roger Amos Kañaa   +3 more
wiley   +1 more source

Therapeutic Potentials of Psychedelic Drugs

, 2016
This article presents a brief look into the possible therapeutic Potentials of the psychedelic drugs LSD, psilocybin and DMT. It explores the theories of how these substances may have beneficial effects across the spectrum of pathologies from ...
Jesuthasan, Prathesh
core  

Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report

BMC Psychiatry
Background Psychedelic-assisted therapy has gained growing interest to improve a range of mental health outcomes. In response, numerous training programs have formed to train the necessary workforce to deliver psychedelic therapy.
John Perna, Justin Trop, Roman Palitsky, Zachary Bosshardt, Helen Vantine, Boadie W. Dunlop, Ali J. Zarrabi   +6 more
doaj   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Assessing the psychedelic experience

, 2021
The Mystical Experience Questionnaire (MEQ) is used in psychedelic research to assess a specific experience and predict treatment outcome. We suggest that the mystical terminology used in the MEQ is unnecessary to measure the underlying phenomenon, that ...
Josjan Zijlmans, Noah van Dongen, Joel Bornemann   +2 more
core   +1 more source